Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Study sponsor: Revolution Medicines, Inc. · RVMD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-06Estimated
Enrollment · participants616Estimated
Source updated2026-10-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.